



Quantitative Systems Pharmacology (QSP) Multiple Myeloma Model*

Software capable of predicting efficacy for your novel therapeutics. Over 20 phase 2/3 clinical trials are used in training this model, spanning over 25 drug regimens and 14 distinct therapeutic agents, including steroids, proteasome inhibitors, immunomodulatory agents, T cell engagers, CAR-T therapies, monoclonal antibodies and combinations thereof.



Key Applications

- Predict efficacy for late-stage therapeutics under development, including T cell engagers and CAR-T therapy
- Compare different therapeutics with the same or similar targets or against existing treatments
- Determine patient subgroups of interest based on baseline patient features or response to prior lines of therapy
- Identify optimal dosing strategies for specific scenarios of interest

Key Features

- Convenient, efficient, and thorough generation and calibration of virtual populations
- Includes both qualitative and quantitative data during model training
- Represents clinical trials with specific entrance criteria
- Plot and analyze simulation results in the same platform
- Automatically visualize connections between model components
- Export data to other programs for ad hoc analyses

Sound Science



Generates

virtual populations that include inter-patient variability in pathophysiology as well as clinical endpoints



Clinical Data

data constrains contributions of distinct pathways to tumor growth and suppression for numerous therapeutic classes (eg, immunomodulatory drugs, proteasome inhibitors, etc.)



Includes

detailed interactions between the tumor and immune response



Simulates

cellular and biochemical processes across multiple scales, from cytokine concentrations to clinical response endpoints



Considers

an initial population of relapsed or refractory patients, with a focus on a subgroup of patients refractory to lenalidomide



Core

oncological processes are explicitly represented, including changes in antigen expression relevant to therapy, such as BCMA

Connect with us: 🖪 😉 in 👨









